Summit Financial Strategies 13F: New $201K Stake in MDT
An institutional filing reveals Summit Financial Strategies picked up a new stake in medical device maker Medtronic plc.
Reviewed by automated data checks against the source filing. How we make and check alerts
Summit Financial Strategies opened a new position of 2,327 shares in Medtronic plc ($MDT), according to a 13F filing with the SEC dated October 14, 2026. It reported 2,327 shares worth $200,797 at the end of the quarter.
Since the filing, $MDT is up 0.6% to date (from the $94.23 close on Oct 14, 2026).
Find the original: Summit Financial Strategies 13F filings on SEC EDGAR
MDT
Medtronic plc
Key Points
- Summit Financial Strategies opened a new position in Medtronic plc with 2,327 shares valued at $200,797.
- Medtronic shares trade around $94.46, sitting above their 50-day and 200-day moving averages.
- The company reports its next financial results on November 17, 2026.
Get $MDT trade alerts by text
We text you when insiders, Congress or big funds trade $MDT. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Medtronic plc alert may contain errors. Disclosures
In a Form 13F filing on October 14, 2026, Summit Financial Strategies disclosed a brand-new stake in Medtronic plc (NYSE: MDT), picking up 2,327 shares valued at approximately $200,797. Because 13F filings look backward at holdings from the end of the reported period, this report reflects positions held at that time and may not match the fund's current holdings today.
Other Institutional Activity in Medtronic plc
Other major institutional investors adjusted their positions in the medical device company during recent periods, with large asset managers buying up additional shares.
Medtronic plc Stock Down 1.0%
Medtronic stock recently traded around $94.46 as of October 16, 2026. That puts the shares up about 4.1% above their 50-day moving average of $90.71 and roughly 7.0% above their 200-day moving average of $88.31. The stock sits about 11.2% below its 52-week high of $106.33 and 28.9% above its 52-week low of $73.31. Keep in mind that 13F reports only show historical snapshot data from past quarters.
Recent Earnings
Medtronic posted trailing-twelve-month revenue of $37.54 billion and earnings of $4.07 per share, alongside a net profit margin of 13.9% and a return on equity of 10.6%. The company's next earnings report is expected on November 17, 2026.
Dividend
Medtronic pays an annual dividend of $2.88 per share, which works out to a dividend yield of roughly 3.02% based on a payout ratio of 70.0%.
Insider Buying and Selling at Medtronic plc
Company insiders executed several transactions prior to the filing, including sales by officers Harry Skip Kiil and Matthew R. Walter.
Analysts Set New Price Targets
Wall Street firms maintain coverage on the stock, with Truist Securities, UBS, TD Cowen, Barclays, and BTIG issuing ratings and price targets ahead of the filing.
About Medtronic plc
Medtronic plc develops and sells device-based medical therapies for healthcare systems, physicians, and patients worldwide through its cardiovascular, neuroscience, and medical surgical portfolios.
Bottom Line
Investors tracking Summit Financial Strategies will need to wait for subsequent SEC filings to see if the firm maintains its stake. Watch for Medtronic's upcoming earnings report on November 17, 2026, for fresh details on the company's financial health. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.
Related Filing Alerts
Source: Summit Financial Strategies's 13F filing on $MDT (Oct 14, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Summit Financial Strategies 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts